Navigation Links
Keryx Biopharmaceuticals, Inc. Announces First Quarter 2012 Financial Results
Date:5/8/2012

statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: our ability to successfully adjust our strategy and reduce our operating expenses following the termination of the KRX-0401 license agreement; our ability, and our Japanese partner's ability, to successfully and cost-effectively complete clinical trials for Zerenex (ferric citrate); the risk that the data (both safety and efficacy) from the ongoing Phase 3 trials for Zerenex (ferric citrate) will not coincide with the data analyses from previous clinical trials reported by the Company; our ability to meet anticipated development timelines for Zerenex due to clinical trial results, manufacturing capabilities or other factors; and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at http://www.keryx.com. The information found on our website is not incorporated by reference into this press release and is included for reference purposes only.

KERYX CONTACT:
Lauren Fischer
Director – Investor Relations
Keryx Biopharmaceuticals, Inc.
Tel: 212.531.5965
E-mail: lfischer@keryx.com

 Keryx Biopharmaceuticals, Inc.Selected Consolidated Financial Data(In Thousands, Except Share and Per Share Amounts)Statements of Operations Information (Unaudited):
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
2. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
3. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
4. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
5. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
6. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
7. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
8. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
9. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
10. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
11. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... 2014 Legislation backed by the drugstore ... Pharmacies Act of 2014") championing so-called "any willing ... the availability of lower cost preferred pharmacy networks ... the next 10 years, according to new research ... Care Management Association (PCMA). The drugstore ...
(Date:7/22/2014)... , July 22, 2014  Eyeon Therapeutics has received ... treatment based on a charged hydrophilic polymer developed at ... has been shown to be safe and effective in ... MD, CEO states, "This first set of claims around ... way to moving this technology into the commercial phase.  ...
(Date:7/22/2014)... Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and ... lots of Fluzone ® (Influenza Vaccine) for the 2014-2015 ... Food and Drug Administration (FDA) for distribution. The lots were ... least 65 million doses of seasonal influenza vaccine manufactured by ... providers and pharmacies in August. The U.S. ...
Breaking Medicine Technology:New Study: H.R. 4577 to Cost $21 Billion over 10 Years 2New Study: H.R. 4577 to Cost $21 Billion over 10 Years 3Particle Sciences and Eyeon Therapeutics Receive Patent on Novel Dry Eye Technology 2Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 2Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 3Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 4Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 5Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 6Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 7
... Aug. 17 The hospital patient room of the future ... New Jersey, providing lessons that stand to benefit hospitals and ... building a new hospital in Plainsboro, NJ, to replace its ... a fully functioning replica of the new hospital,s proposed patient ...
... Inc. (NYSE Amex: ULU ) today announced its financial ... the second quarter of 2010, the Company reported a net loss of ... $2.9 million, or $0.04 per share, for the same period last year. ... net loss of $3.5 million, or $0.04 per share, compared with a ...
Cached Medicine Technology:Hospital Room of the Future Debuts in New Jersey 2Hospital Room of the Future Debuts in New Jersey 3Hospital Room of the Future Debuts in New Jersey 4ULURU Inc. Reports Second Quarter 2010 Financial Results 2ULURU Inc. Reports Second Quarter 2010 Financial Results 3ULURU Inc. Reports Second Quarter 2010 Financial Results 4ULURU Inc. Reports Second Quarter 2010 Financial Results 5ULURU Inc. Reports Second Quarter 2010 Financial Results 6
(Date:7/22/2014)... Dr. Dental is excited to announce the ... visitors in mind, one of the main differences from the ... makes navigation very easy. Dr. Dental is renowned for having ... the dentist affordable, convenient and fun, and the new website ... an appointment scheduling system right on the home page where ...
(Date:7/22/2014)... 22, 2014 The 2014 Warrior-Family ... Ronald Reagan Building and International Trade Center in ... Families and Civilian Communities,” will be held from ... 7:30 a.m.) and cohosted by the Military Officers ... Industrial Association (NDIA). USAA is the Executive Sponsor ...
(Date:7/22/2014)... Aaron Marshall, Corporate Counsel at Northrop Grumman, will serve ... for the 2014-2015 fiscal year. He joined the Board ... "“Serving on the HASA board has given me a broader, ... remember how much others need help." , ABOUT AARON MARSHALL:, ... a B.S. in Finance from the University of Delaware. Currently, ...
(Date:7/22/2014)... Steven Reinberg HealthDay ... Two treatments that break up blood clots deep in the ... death risk. However, one results in a greater risk of ... cost of the other treatment, a new study finds. ... vein thrombosis (DVT) -- is blood-thinning medications and compression stockings. ...
(Date:7/22/2014)... The American Society of Hematology (ASH) will honor ... Los Angeles with the 2014 E. Donnall Thomas ... the discovery of the iron-regulatory hormone hepcidin and investigation ... after the Nobel Prize Laureate and past Society president ... hematology that have represented a paradigm shift or significant ...
Breaking Medicine News(10 mins):Health News:Dr. Dental Reveals Exciting New Website 2Health News:2014 Warrior-Family Symposium Focuses on Transitioning Forward 2Health News:2014 Warrior-Family Symposium Focuses on Transitioning Forward 3Health News:New Board President for Baltimore-based Nonprofit 2Health News:Study Casts Doubt on Costly Treatment for Leg Clots 2Health News:Study Casts Doubt on Costly Treatment for Leg Clots 3Health News:Tomas Ganz, M.D., Ph.D., to present 2014 ASH E. Donnall Thomas Lecture 2Health News:Tomas Ganz, M.D., Ph.D., to present 2014 ASH E. Donnall Thomas Lecture 3
... at Telemedicine Conference in Las Vegas, Booth 1206 LAS ... Suisse AG (Fora Care,s Swiss sister company) announced today ... American Telemedicine Association (ATA) conference through April 28 at ... The veteran telemedicine companies are presenting at the ...
... following is being issued by American Stroke Association: , , ... It,s better to find out than miss out. Be aware ... and their side effects. Ask if your home should be modified ... doctor, nurse or therapist to clarify any unanswered questions or to ...
... Daily exposure to toxins in the products we ... insecticides, are creating a toxic load on our bodies ... In light of increased awareness of our environmental exposures, ... ) announced today the release of three new testing ...
... campaign reflects diverse communities; focuses on health advocacy ... Kaiser Permanente is adding two new television commercials ... campaign this month. The 30-second ads, titled "Mural" ... communities it serves, as well as the organization,s ...
... painful flare-ups, study finds , , MONDAY, April 27 (HealthDay ... and inexpensive way of treating children with eczema, according ... 17 percent of school-age children, can affect youngsters, appearance, ... , Eczema-related itching can be so bad that children ...
... have a ,baseline, prostate cancer screen at 40, but yearly ... 27 (HealthDay News) -- New guidelines on prostate cancer screening ... for many men, but the same guidelines call for a ... 50. , A prostate-specific antigen (PSA) test to detect early ...
Cached Medicine News:Health News:Fora Care and Fora Care Suisse AG Launch Diabetes Telehealth Solution at ATA 2Health News:Fora Care and Fora Care Suisse AG Launch Diabetes Telehealth Solution at ATA 3Health News:15 Tips Caregivers Should Know After a Loved One Has Had a Stroke 2Health News:15 Tips Caregivers Should Know After a Loved One Has Had a Stroke 3Health News:Metametrix Announces New Toxic Effects Profiles to Help Combat Growing Concerns About Toxicity and Health 2Health News:Kaiser Permanente Continues to Spread Health With New Ads Debuting in April 2Health News:Kaiser Permanente Continues to Spread Health With New Ads Debuting in April 3Health News:Diluted Bleach Baths Ease Kids' Eczema 2Health News:Experts Back Away From Annual PSA Test 2Health News:Experts Back Away From Annual PSA Test 3
... matrix constructed of cross-linked collagen fibers ... through a proprietary 360 accretion process. ... aspirate, Healos provides an excellent environment ... differentiation. The hydroxyapatite-coated collagen microfibers in ...
Sharp Weitlaner Retractor....
Weitlaner retractor, blunt....
Bruns (Volkmann) bone curette, with Novotex plastic handle (autoclavable in autoclave up to 143C by 3 bar), 9, oval....
Medicine Products: